FDA Hearing. What FDA Failed to Disclose: 1991, 2006.
AHRP Testimony presented by Vera Sharav, December 2006. PowerPoint slides (843 kb file).
Similar Posts
Study: Antipsychotics Not Effective for Childhood Schizophrenia
Industry’s blockbuster sellers–the atypical antipsychotics performed WORSE than their cheaper, non-patented precursors.
Coroner calls for withdrawal of Seroxat (PAXIL)
Coroner calls for withdrawal of Seroxat (PAXIL) March 13, 2002 Following the death of a 56 year old retired headmaster within two weeks of taking the antidepressant, Seroxat (PAXIL), a British coroner told a court “”I have grave concerns that this is a dangerous drug that should be withdrawn until…
FDA Underhanded Tactics Against Medical Officer Who Blew the Whistle
FDA Underhanded Tactics Against Medical Officer Who Blew the Whistle Mon, 29 Nov 2004 The Food and Drug Administration is the epicenter of a collision between medical officers in the drug safety office and senior officials in managerial positions whose focus is on facilitating new drug approvals. Officials at the…
AHRQ No Evidence to Support Off-Label Uses of Atypical Antipsychotics
"Most off-label use occurs without scientific support."
What’s New? – Alliance for Human Research Protection
To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
New Diabetes Drug Increases Mortality / Morbidity – FDA "approvable" letter Challenged
New Diabetes Drug Increases Mortality / Morbidity – FDA “approvable” letter Challenged Fri, 21 Oct 2005 Today’s newspaper reports about a lethal new diabetes drug that the FDA was poised to approve makes abundantly clear that The New York Times got it wrong when it gave the FDA high marks…